Glioblastoma multiforme (GBM) represents one of the most common aggressive types of primary brain tumors.
Despite advances in surgical resection, novel neuroimaging procedures, and the most recent adjuvant radiotherapy and
chemotherapy, the median survival after diagnosis is about 12-14 months. Targeting migrating GBM cells is a key research
strategy in the fight against this devastating cancer. Though the vast majority of the primary tumor focus can be
surgically resected, these migrating cells are responsible for its universal recurrence. Numerous strategies and technologies
are being explored to target migrating glioma cells, with small molecular inhibitors as one of the most commonly
studied. Small molecule inhibitors, such as protein kinase inhibitors, phosphorylation site inhibitors, protease inhibitors,
and antisense oligonucleotides show promise in slowing the progression of this disease. A better understanding of these
small molecule inhibitors and how they target various extra- and intracellular signaling pathways may eventually lead to a
cure for GBM.
Keywords: Glioblastoma, glioma cell, migration, small molecular inhibitor, brain tumors, protein kinase inhibitors, phosphorylation site inhibitors, protease inhibitors, antisense oligonucleotides, intracellular signaling pathways
Rights & PermissionsPrintExport